Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocytes-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis

References

• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61.
   PubMed Web of Science ®Google Scholar
• Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000;2:361–7.
   PubMedGoogle Scholar
• Tamer IH, Miiller-Ladner U, Gay S. Emerging targets of biologic therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2007;3:336–45.
   PubMedGoogle Scholar
• Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler 0. Microparticles as regulators of inflammation. Novel players of cellular crosstalk in the rheumatic disease. Arthritis Rheum. 2005;52:3337–48.
   Google Scholar
• Gasser 0, Schifferli JA. Microparticles released by human neu-trophils adhere to erythrocytes in the presence of complement. Exp Cell Res. 2005;307:381–7.
   Google Scholar
• Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leu-kemia. 2006;20:1487–95.
   Google Scholar
• Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from circulating from vascular cells in resulting vascular function. Am J Physiol Heart Circ Physiol. 2005;288:1004–9.
   Web of Science ®Google Scholar
• Berckmans RJ, Nieuwland R, Tak PP, Boing AN, Romijn FP, Kraan MC, et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively vai a factor VII-dependent mechanism. Arthritis Rheum. 2002;46: 2857–66.
   PubMed Web of Science ®Google Scholar
• Knliff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002;46:1498–503.
   Google Scholar
• Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T, et al. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1999;42:431–7.
   Google Scholar
• Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis-results of a randomized pilot trial. Dig Dis Sci. 2007;52:2044–53.
   PubMedGoogle Scholar
• Ueki Y, Yamasaki S, Kanamoto Y, Kawazu T, Yam M, Matsumoto K, et al. Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheu-matology (Oxford). 2000;39:165–71.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Saito K, Kondo M, Hidaka T, Ueki Y, Tanaka Y. Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. Mod Rheumatol. 2007;17:481–5.
   PubMedGoogle Scholar
• Hidaka T, Suzuki K. The mechanism of the efficiency of leuk-ocytapheresis on rheumatoid arthritis. Ther Apher. 1997;1:215–8.
   PubMedGoogle Scholar
• Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Okada M, Ishizuka T, et al. Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. Ther Apher. 1999;3: 178–85.
   Google Scholar
• Ueki Y, Nakamura H, Kanamoto Y, Miyazaki M, Yano M, Matsumoto K, et al. Comparison of lymphocyte depletion and clinical effectiveness on filtration leukocytapheresis in patients with rheumatoid arthritis. Ther Apher. 2001;5:455–61.
   PubMedGoogle Scholar
• Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T, et al. Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher. 2001;16:74–81.
   PubMed Web of Science ®Google Scholar
• Andoh A, Ogawa A, Kitamura K, Inatomi 0, Fujino S, Tsujikawa T, et al. Suppression of interleukin- lbeta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapher-esis therapy in patients with ulcerative colitis. J Gastroenterol. 2004;39:1150–7.
   Google Scholar
• Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kikuyama M, et al. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood fol-lowing leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol. 2005;11:3085–90.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include 28-joint counts. Development and validation in a pro-spective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38: 44–8.
   Google Scholar
• Jy W, Horstman LL, Jimenez JJ, Ahn YS, Biro E, Nieuwland R, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004;2:1842–51.
   PubMed Web of Science ®Google Scholar
• Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev. 2007;21:99–111.
   PubMed Web of Science ®Google Scholar
• Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost. 2008;99:264–70.
   Google Scholar
• Hutchinson RM, Davis P, Jayson MI. Thrombocytosis in rheu-matoid arthritis. Ann Rheum Dis. 1976;35:138–42.
   PubMed Web of Science ®Google Scholar
• Fan M, Scott DL, Constable TJ, Hawker RJ, Hawkins CF, Stuart J. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis. 1983;42:545–9.
   PubMedGoogle Scholar
• Fukunaga K, Fukuda Y, Yokoyama Y, Ohnishi K, Kusaka T, Kosaka T, et al. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol. 2006;41:524–32.
   PubMedGoogle Scholar
• Yagi Y, Andoh A, Inatomi 0, Bamba S, Tsujikawa T, Fujiyama Y, et al. Modulation of platelet aggregation responses by leuko-cytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol. 2006;41:540–6.
   Google Scholar
• Gasser 0, Hess C, Miot S, Deon C, Sanchez JC, Schifferli JA. Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils. Exp Cell Res. 2003;285:243–57.
   Google Scholar
• Hirayama A, Nagase S, Ueda A, Ishizu T, Taru Y, Yoh K, et al. Oxidative stress during leukocyte absorption apheresis. J Clin Apher. 2003;18:61–6.
   PubMedGoogle Scholar
• Daniel L, Fakhouri F, Joly D, Mouthon L, Nusbaum P, Grunfeld JP, et al. Increase of circulating neutrophil and platelet micro-particles during acute vasculitis and hemodialysis. Kidney Int. 2006;69:1416–23.
   PubMed Web of Science ®Google Scholar
• Gasser 0, Schifferli JA. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. Blood. 2004;104:2543–8.
   Google Scholar
• Hoffmann PR, de Cathelineau AM, Ogden CA, Levenier Y, Bratton DL, Daleke DL, et al. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J Cell Biol. 2001;155:649–59.
   PubMed Web of Science ®Google Scholar